These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 16410038)

  • 1. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
    Majumder S; Dutta P; Mukherjee P; Datta ER; Efferth T; Bhattacharya S; Choudhuri SK
    Cancer Lett; 2006 Nov; 244(1):16-23. PubMed ID: 16410038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deactivation of P-glycoprotein by a novel compound, oxalyl bis (N-phenyl) hydroxamic acid.
    Choudhuri SK
    Neoplasma; 2002; 49(4):272-7. PubMed ID: 12382028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Redox active copper chelate overcomes multidrug resistance in T-lymphoblastic leukemia cell by triggering apoptosis.
    Ganguly A; Basu S; Banerjee K; Chakraborty P; Sarkar A; Chatterjee M; Chaudhuri SK
    Mol Biosyst; 2011 May; 7(5):1701-12. PubMed ID: 21409205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.
    Majumder S; Dutta P; Mookerjee A; Choudhuri SK
    Chem Biol Interact; 2006 Feb; 159(2):90-103. PubMed ID: 16289015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
    Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
    J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
    Chen G; Waxman DJ
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
    Arora A; Seth K; Kalra N; Shukla Y
    Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel manganese complex, Mn-(II) N-(2-hydroxy acetophenone) glycinate overcomes multidrug-resistance in cancer.
    Ghosh RD; Banerjee K; Das S; Ganguly A; Chakraborty P; Sarkar A; Chatterjee M; Choudhuri SK
    Eur J Pharm Sci; 2013 Jul; 49(4):737-47. PubMed ID: 23665413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
    Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
    Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro.
    Choudhuri SK; Chatterjee A
    Anticancer Drugs; 1998 Oct; 9(9):825-32. PubMed ID: 9840730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo.
    Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W
    J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new apoptosis inhibitor, CIAPIN1 (cytokine-induced apoptosis inhibitor 1), mediates multidrug resistance in leukemia cells by regulating MDR-1, Bcl-2, and Bax.
    Li X; Hong L; Zhao Y; Jin H; Fan R; Du R; Xia L; Luo G; Fan D
    Biochem Cell Biol; 2007 Dec; 85(6):741-50. PubMed ID: 18059532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance.
    Abulrob AN; Mason M; Bryce R; Gumbleton M
    J Drug Target; 2000; 8(4):247-56. PubMed ID: 11144235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
    Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis.
    Mookerjee A; Mookerjee Basu J; Dutta P; Majumder S; Bhattacharyya S; Biswas J; Pal S; Mukherjee P; Raha S; Baral RN; Das T; Efferth T; Sa G; Roy S; Choudhuri SK
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4339-49. PubMed ID: 16857809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
    Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
    Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.